GSKGlaxoSmithKlineSigning up patients
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
Neoplasms, Prostate
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 85 (planned)
- Started
- Jun 12, 2025
- Main results expected
- Oct 26, 2027
- Fully finished
- Aug 9, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with dose limiting toxicities (DLTs) during DLT observation period
Measured over: Up to 28 days
Number of participants with adverse events (AEs), serious adverse events (SAEs), by Severity
Measured over: Up to approximately 29 months
Number of participants with AEs leading to dose modifications
Measured over: Up to approximately 29 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06990880 · record last updated 2026-10-05 · checked 2026-11-09 15:47 UTC